BeyondSpring Inc. Professional Fees
BeyondSpring Inc. (BYSI) reported Professional Fees of $245.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProfessionalFees · last filed 2026-08-14
- BeyondSpring Inc. professional fees for the quarter ending 2026-06-30 was $245.00K, a 47.87% decline year-over-year.
- BeyondSpring Inc. professional fees for the quarter ending 2026-03-31 was $639.00K, a 33.16% decline year-over-year.
- BeyondSpring Inc. professional fees for the quarter ending 2025-12-31 was $260.00K.
- BeyondSpring Inc. professional fees for the quarter ending 2025-09-30 was $256.00K, a 68.93% decline year-over-year.
- BeyondSpring Inc. professional fees for fiscal 2025 was $1.96M, a 35.78% increase from fiscal 2024.
- BeyondSpring Inc. professional fees for fiscal 2024 was $1.44M, a 51.92% decline from fiscal 2023.
- BeyondSpring Inc. professional fees for fiscal 2023 was $3.00M.
| Period end | Professional Fees 3 month | Professional Fees 6 month | Professional Fees 9 month | Professional Fees 12 month |
|---|---|---|---|---|
| 2026-06-30 | $245.00K 10-Q · filed 2026-08-14 | $832.00K 10-Q · filed 2026-08-14 | $1.14M derived: sum of 3 quarters · filed 2026-08-14 | $1.40M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $639.00K 10-Q · filed 2026-05-13 | $899.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.16M derived: sum of 3 quarters · filed 2026-05-13 | $1.63M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $260.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $516.00K derived: sum of 2 quarters · filed 2026-03-25 | $986.00K derived: sum of 3 quarters · filed 2026-08-14 | $1.96M 10-K · filed 2026-03-25 |
| 2025-09-30 | $256.00K 10-Q · filed 2025-11-12 | $726.00K derived: sum of 2 quarters · filed 2026-08-14 | $1.70M 10-Q · filed 2025-11-12 | $1.56M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $470.00K 10-Q · filed 2026-08-14 | $1.44M 10-Q · filed 2026-08-14 | $1.30M derived: sum of 3 quarters · filed 2026-08-14 | $2.13M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $956.00K 10-Q · filed 2026-05-13 | $835.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.66M derived: sum of 3 quarters · filed 2026-05-13 | $2.60M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$121.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $703.00K derived: sum of 2 quarters · filed 2026-03-25 | $1.65M derived: sum of 3 quarters · filed 2026-03-25 | $1.44M 10-K · filed 2026-03-25 |
| 2024-09-30 | $824.00K 10-Q · filed 2025-11-12 | $1.77M derived: sum of 2 quarters · filed 2025-11-12 | $1.56M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $943.00K 10-Q · filed 2025-08-13 | $1.26M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $318.00K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $3.00M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |